Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Aristotle University of Thessaloniki · University of Pisa · +4 more institutions
Abstract
Abstract Aims/hypothesis Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval. Individual trials have assessed the clinical profile of tirzepatide vs different comparators. We conducted a systematic review and meta-analysis to assess the efficacy and safety of tirzepatide for type 2 diabetes. Methods We searched PubMed, Embase, Cochrane and ClinicalTrials.gov up until 27 October 2021 for randomised controlled trials with a duration of at least 12 weeks that compared once-weekly tirzepatide 5, 10 or 15 mg with placebo or other glucose-lowering drugs in adults with type 2 diabetes…
Citation impact
- FWCI
- 32.12
- Percentile
- 100%
- References
- 31
Authors
7- TKThomas KaragiannisCorresponding
Aristotle University of Thessaloniki
- IAIoannis Avgerinos
Aristotle University of Thessaloniki
- ALAris Liakos
Aristotle University of Thessaloniki
- SDStefano Del Prato
University of Pisa
- DRDavid R. Matthews
Churchill Hospital, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, Manchester College
Topics & keywords
- Medicine
- Internal medicine
- Discontinuation
- Adverse effect
- Type 2 diabetes
- Placebo
- Diabetes mellitus
- Glucagon-like peptide 1 receptor
- Good health and well-being